COCP - Company ID 0001412486
The table below shows Cocrystal Pharma, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $225.00K | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.37M | $954.00K | $1.12M | $1.36M | $3.24M | $4.31M |
| SG&A |
Cocrystal Pharma, Inc. reported annual revenue of $2.01M for fiscal year 2020. That is down 69.3% from $6.56M in fiscal 2019. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.21M |
| $1.14M |
| $986.00K |
| $981.00K |
| $1.80M |
| $1.14M |
| Operating income | -$2.36M | -$2.09M | -$2.11M | -$2.34M | -$5.04M | -$5.45M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$2.30M | -$2.05M | -$2.06M | -$2.30M | -$4.94M | -$5.34M |
| EPS (diluted) | -$0.17 | -$0.19 | -$0.20 | -$0.23 | -$0.49 | -$0.53 |